UNLIMITED TURBO LONG - LABORATORY CO. OF AMER. HLD | Real-time Boerse Frankfurt Warrants 20:50:33 17/05/2024 BST | ||
| 2.6 EUR | -10.96% |
|
| Current month | +31.31% | ||
| 1 month | +36.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about LABORATORY CORPORATION OF AMERICA HOLDINGS
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 2.6 | -13.04% |
| 16/05/24 | 2.99 | +3.82% |
| 15/05/24 | 2.88 | +7.06% |
| 14/05/24 | 2.69 | +0.75% |
| 13/05/24 | 2.67 | +11.72% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 08:50 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | LABORATORY CORPORATION OF AMERICA HOLDINGS |
| Issuer | 
BNP Paribas
|
| WKN | PC6JY6 |
| ISIN | DE000PC6JY61 |
| Date issued | 13/03/2024 |
| Strike | 183.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.59 € |
|---|---|
| Lowest since issue | 1.48 € |
Company Profile
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows:
- clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services;
- development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies.
Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Sector
-
Ratings for Laboratory Corporation of America Holdings
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Laboratory Corporation of America Holdings
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
210.6
USD
Average target price
239.7
USD
Spread / Average Target
+13.81%
- Stock Market
- Certificates
- Certificat
